ALLMedicine™ Severe Chronic Neutropenia Center

Sep 9th, 2020 - Agammaglobulinemia is the most profound primary antibody deficiency that can occur due to an early termination of B-cell development. We here investigated 3 novel patients, including the first known adult, from unrelated families with agammaglobul...

Nov 25th, 2019 - Registries provide 'real world' perspectives on the natural history and outcomes for many clinical conditions. The purpose of this review is to identify registries for nonmalignant hematological disease and to describe the operation of a successfu...

Mar 1st, 2019 - Warts Hypogammaglobulinemia Immunodeficiency Myelokathexis (WHIM) syndrome is a primary immunodeficiency characterized by recurrent bacterial infections, severe chronic neutropenia, with lymphopenia, monocytopenia and myelokathexis which is caused...

Jul 22nd, 2018 - Photo by Bill Branson Vials of drug The US Food and Drug Administration (FDA) has approved the leukocyte growth factor Nivestym™ (filgrastim-aafi), a biosimilar to Neupogen (filgrastim). Nivestym is approved to treat patients with nonmyeloid malig.

Mar 9th, 2018 - Withdrawn by the publisher.

Sep 9th, 2020 - Agammaglobulinemia is the most profound primary antibody deficiency that can occur due to an early termination of B-cell development. We here investigated 3 novel patients, including the first known adult, from unrelated families with agammaglobul...

Nov 25th, 2019 - Registries provide 'real world' perspectives on the natural history and outcomes for many clinical conditions. The purpose of this review is to identify registries for nonmalignant hematological disease and to describe the operation of a successfu...

Mar 1st, 2019 - Warts Hypogammaglobulinemia Immunodeficiency Myelokathexis (WHIM) syndrome is a primary immunodeficiency characterized by recurrent bacterial infections, severe chronic neutropenia, with lymphopenia, monocytopenia and myelokathexis which is caused...

Jul 22nd, 2018 - Photo by Bill Branson Vials of drug The US Food and Drug Administration (FDA) has approved the leukocyte growth factor Nivestym™ (filgrastim-aafi), a biosimilar to Neupogen (filgrastim). Nivestym is approved to treat patients with nonmyeloid malig.

Mar 9th, 2018 - Withdrawn by the publisher.

Jul 22nd, 2018 - Photo by Bill Branson Vials of drug The US Food and Drug Administration (FDA) has approved the leukocyte growth factor Nivestym™ (filgrastim-aafi), a biosimilar to Neupogen (filgrastim). Nivestym is approved to treat patients with nonmyeloid malig.

Mar 6th, 2015 - WASHINGTON -- The FDA has approved Sandoz's copy of filgrastim, the first so-called biosimilar drug to win the agency's OK. To be sold as Zarxio with a generic name of filgrastim-sndz, the product will compete against Amgen's original drug, Neupog...